The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis

Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis

October 5, 2021 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to unbridled systemic inflammation and accelerated atherosclerosis. The trouble is, now that we know about it, what is our responsibility as rheumatologists? Cardiology is its own specialty for a reason, isn’t it?

You Might Also Like
  • Identifying Cardiovascular Risk Factors in Psoriatic Arthritis
  • Researcher Studies Ways to Cut Cardiovascular Disease Risk in Rheumatoid Arthritis Patients
  • Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes
Also By This Author
  • Multidisciplinary Guidance for Pulmonary Disease in Sjögren’s Syndrome

This article focuses on the elevated CV risk in PsA and discusses practical ways in which we can practice rheumatology, but also protect our patients from preventable CV harm.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Evidence

Inflammatory arthritis is associated with an increased risk of CV disease. Many studies have described an increased risk of CV events associated with gout and rheumatoid arthritis, but the risk with psoriatic arthritis was not as well reported until recently.

In the early 2000s, researchers identified psoriasis as an independent risk factor for myocardial infarction even after adjusting for other CV risk factors (e.g., age, sex, tobacco use).1 It is now clear that PsA patients are at increased risk of CV disease as well.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A 2017 systematic review and meta-analysis of observational studies in patients with PsA showed a 43% increased risk of having or developing CV disease, and a 55% increased risk of incident CV events in patients with PsA compared with the general population.2 The increased CV risk was observed across a variety of types of CV events: myocardial infarction, cerebrovascular diseases and heart failure.

Does Treating to Target Lower CV Risk?

As rheumatologists, we hope treating to target will have protective CV effects in patients with PsA, but confirmatory data are not yet available. It is scientifically sound to theorize that controlling systemic inflammation will have protective CV benefits, and this is an area of active research in both cardiology and rheumatology communities.

Dr. Shapiro

I recall being excited and stunned by the 2017 New England Journal of Medicine trial investigating the use of canakinumab, an anti-interleukin (IL) 1β antagonist, in decreasing CV risk in patients with atherosclerotic disease.3 Over 10,000 patients with previous myocardial infarction and an elevated high-sensitivity C-reactive protein level were administered canakinumab every three months, with the primary efficacy end point being nonfatal myocardial infarction, nonfatal stroke or CV death.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions Tagged With: PsA Resource Center, Psoriatic Arthritis

You Might Also Like:
  • Identifying Cardiovascular Risk Factors in Psoriatic Arthritis
  • Researcher Studies Ways to Cut Cardiovascular Disease Risk in Rheumatoid Arthritis Patients
  • Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes
  • Psoriatic Arthritis: Recognize, Manage Comorbidities

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)